Ongoing clinical trials (NCT04464967, NCT04144569) are evaluating the addition of a HER2 inhibitor to an EGFR inhibitor, or an immune checkpoint inhibitor, to overcome the acquired resistance in patients with HER2-mutated NSCLC. Here, ERBB2 is linked to non-small cell lung carcinoma.